Novartis Ag (NVS) Cost of Revenue (2009 - 2026)

Novartis Ag has reported Cost of Revenue for 18 years, with the latest figure at $3.7 billion in Q2 2026.

• Quarterly Cost of Revenue rose 11.68% year-over-year to $3.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.5 billion (down 13.74% YoY) and the FY2025 annual result came in at $13.7 billion, up 6.8% from the prior year.
• Cost of Revenue improved to $3.7 billion in Q2 2026 per NVS's latest filing, from $3.3 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $7.6 billion in Q4 2022 and troughed at $236.0 million in Q3 2022.
• A 5-year average of $3.5 billion and a median of $3.3 billion in 2023 frame the typical range for Cost of Revenue.
• The widest YoY moves for Cost of Revenue: up 13.19% in 2023, down 16.75% in 2023.
• Over 5 years, Cost of Revenue stood at $7.6 billion in 2022, then decreased by 16.75% to $6.3 billion in 2023, then dropped by 1.01% to $6.3 billion in 2024, then tumbled by 47.01% to $3.3 billion in 2025, then increased by 11.68% to $3.7 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.7 billion, $3.3 billion, and $6.3 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.